Do You Have These Biotech Stocks In Your Portfolio?

The success rate of phase I clinical programs is the highest, say 63%, while it is the lowest for phase II trials - i.e. 30%. The phase III trials, which are the longest and most expensive trials to conduct, are said to have a success rate of 58%, according to a new report from the Biotechnology Innovation Organization on "Clinical Development Success Rates" over the past decade (2006-2015).

from RTT - Biotech http://ift.tt/2d2YqsY
via IFTTT